<unk>  (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically,<unk>  inhibits the hepatitis C viral enzyme NS3/4A serine protease.<unk>  is only indicated for use against hepatitis C genotype 1 viral infections and has not been proven to be safe or effective when used for other genotypes of the virus. The standard therapy of pegylated interferon and ribavirin is less effective than<unk>  in those with genotype 1.
Telaprevir
Paritaprevir
Glecaprevir
Dasabuvir
Abacavir
Indinavir
Ledipasvir
Saquinavir